Based on data from 2024, an estimated 8 million people in the US have used psilocybin for various purposes in the last year.

Among Medicare beneficiaries there was a decline in primary care visits, and limited telemedicine use between 2017 and 2023.

Treatments for COVID-19, gout, nicotine dependence, severe hypertriglyceridemia, and thyroid eye disease are under review.

New AAP guidance emphasizes longitudinal assessment and collaborative partnerships to foster healthy mental and emotional development in children.